The many faces of FcγRI: Implications for therapeutic antibody function

Immunological Reviews

Volumn 268, Issue 1, 2015, Pages 160-174

  Swisher, Jennifer F A ^a   Feldman, Gerald M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Fc RI; Immune complexes; Therapeutic antibodies

Indexed keywords

CD64 ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; MONOCLONAL ANTIBODY; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; LIGAND; PROTEIN BINDING; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG RECEPTOR BINDING; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; NEOPLASMS; PROTEIN DOMAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INTERFERON-GAMMA; LIGANDS; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945248970     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12334     Document Type: Review

References (137)

1. Shapiro MA, Swann PG, Ricci MS. Regulatory considerations in the development of monoclonal antibodies for diagnosis and therapy. Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co.: KGaA, Weinheim, Germany, 2007;1231-1262.
2. Deckert PM. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 2009;10:158-175.
3. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
4. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005;23:41-51.
5. Ernst LK, Duchemin AM, Miller KL, Anderson CL. Molecular characterization of six variant Fcgamma receptor class I (CD64) transcripts. Mol Immunol 1998;35:943-954.
6. van Vugt MJ, Reefman E, Zeelenberg I, Boonen G, Leusen JHW, van de Winkel JGJ. The alternatively spliced CD64 transcript Fc gamma Rlb2 does not specify a surface-expressed isoform. Eur J Immunol 1999;29:143-149.
7. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61:189-202.
8. Hulett MD, Hogarth PM. The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol 1998;35:989-996.
9. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcgamma receptor I and its implication in high affinity gamma-immunoglobulin binding. J Biol Chem 2011;286:40608-40613.
10. Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc Natl Acad Sci USA 2015;112:833-838.
11. Kiyoshi M, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun 2015;6:6866.
12. vanVugt MJ, et al. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood 1996;87:3593-3599.
13. Keegan AD, Paul WE. Multichain immune recognition receptors: similarities in structure and signaling pathways. Immunol Today 1992;13:63-68.
14. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519-529.
15. Daeron M. Fc receptor biology. Annu Rev Immunol 1997;15:203-234.
16. Allen JM, Seed B. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science 1989;243:378-381.
17. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, Hogarth PM. FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 2002;16:379-389.
18. Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 1997;90:3187-3194.
19. Groselj-Grenc M, Ihan A, Derganc M. Neutrophil and monocyte CD64 and CD163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes. Mediators Inflamm 2008;2008:202646.
20. Tigalonowa M, Bjerke JR, Matre R. Fc gamma-receptors on Langerhans' cells and keratinocytes in suspension from normal skin characterized using soluble immune complexes and monoclonal antibodies. Acta Derm Venereol 1991;71:99-103.
21. Rahman AA, Teschner M, Sethi KK, Brandis H. Appearance of IgG (Fc) receptor(s) on cultured human fibroblasts infected with human cytomegalovirus. J Immunol 1976;117:253-258.
22. Wojtal KA, et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS ONE 2012;7:e43361.
23. Pan LF, Kreisle RA, Shi YD. Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Clin Exp Immunol 1998;112:533-538.
24. Xia YC, et al. Functional expression of IgG-Fc receptors in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2011;44:665-672.
25. Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. NeuroMol Med 2010;12:164-178.
26. Perussia B, Dayton ET, Lazarus R, Fanning V, Trinchieri G. Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med 1983;158:1092-1113.
27. Guyre PM, Morganelli PM, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 1983;72:393-397.
28. te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 1992;149:4048-4052.
29. Repp R, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78:885-889.
30. te Velde AA, Huijbens RJ, de Vries JE, Figdor CG. IL-4 decreases Fc gamma R membrane expression and Fc gamma R-mediated cytotoxic activity of human monocytes. J Immunol 1990;144:3046-3051.
31. Icardi M, Erickson Y, Kilborn S, Stewart B, Grief B, Scharnweber G. CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. J Clin Microbiol 2009;47:3914-3919.
32. Hoffmann JJ. Neutrophil CD64: a diagnostic marker for infection and sepsis. Clin Chem Lab Med 2009;47:903-916.
33. Abeles RD, et al. Neutrophil CD64 expression is elevated in acetaminophen-induced acute liver failure. Am J Respir Crit Care Med 2012;186:1058-1059; author reply 9-60.
34. Zhang H, et al. CD64 expression is increased in patients with severe acute pancreatitis: clinical significance. Gut Liv 2014;8:445-451.
35. O'Hare FM, et al. Neutrophil and monocyte Toll-like receptor 4, CD11b and reactive oxygen intermediates and neuroimaging outcomes in preterm infants. Pediatr Res 2015;78:82-90.
36. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008;226:205-218.
37. de Waal Malefyt R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993;151:6370-6381.
38. Aittomaki S, Pesu M, Groner B, Janne OA, Palvimo JJ, Silvennoinen O. Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol 2000;164:5689-5697.
39. van der Poel CE, et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fc gamma RI, in the presence of monomeric IgG. Blood 2010;116:5327-5333.
40. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119:5640-5649.
41. Bruhns P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113:3716-3725.
42. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 2013;190:4315-4323.
43. Gavin AL, Tan PS, Hogarth PM. Gain-of-function mutations in FcgammaRI of NOD mice: implications for the evolution of the Ig superfamily. EMBO J 1998;17:3850-3857.
44. Osman N, Kozak CA, McKenzie IF, Hogarth PM. Structure and mapping of the gene encoding mouse high affinity Fc gamma RI and chromosomal location of the human Fc gamma RI gene. J Immunol 1992;148:1570-1575.
45. van de Winkel JG, Ernst LK, Anderson CL, Chiu IM. Gene organization of the human high affinity receptor for IgG, Fc gamma RI (CD64). Characterization and evidence for a second gene. J Biol Chem 1991;266:13449-13455.
46. Unkeless JC, Eisen HN. Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages. J Exp Med 1975;142:1520-1533.
47. Albanesi M, et al. Cutting edge: FcgammaRIII (CD16) and FcgammaRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J Immunol 2012;189:5513-5517.
48. Mancardi DA, et al. The high-affinity human IgG receptor Fc gamma RI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013;121:1563-1573.
49. Lu J, Marjon KD, Mold C, Du Clos TW, Sun PD. Pentraxins and Fc receptors. Immunol Rev 2012;250:230-238.
50. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature 2008;456:989-992.
51. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387-402.
52. Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol 2009;29:317-333.
53. Edberg JC, et al. The cytoplasmic domain of human FcgammaRIa alters the functional properties of the FcgammaRI.gamma-chain receptor complex. J Biol Chem 1999;274:30328-30333.
54. Beekman JM, Bakema JE, van der Poel CE, van der Linden JA, van de Winkel JG, Leusen JH. Protein 4.1G binds to a unique motif within the Fc gamma RI cytoplasmic tail. Mol Immunol 2008;45:2069-2075.
55. Li X, et al. The unique cytoplasmic domain of human FcgammaRIIIA regulates receptor-mediated function. J Immunol 2012;189:4284-4294.
56. Beekman JM, et al. Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol 2008;180:3938-3945.
57. Harrison PT, Davis W, Norman JC, Hockaday AR, Allen JM. Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J Biol Chem 1994;269:24396-24402.
58. Beekman JM, Bakema JE, van de Winkel JG, Leusen JH. Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proc Natl Acad Sci USA 2004;101:10392-10397.
59. van Vugt MJ, et al. The Fc gamma RIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. Blood 1999;94:808-817.
60. Beekman JM, et al. Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. J Biol Chem 2004;279:33875-33881.
61. Evans R. Macrophages in syngeneic animal tumours. Transplantation 1972;14:468-473.
62. Nelson DS, Gatti RA. Humoral factors influencing lymphocyte transformation. Prog Allergy 1976;21:261-341.
63. Hibbs JB Jr, Taintor RR, Chapman HA Jr, Weinberg JB. Macrophage tumor killing: influence of the local environment. Science 1977;197:279-282.
64. Weinberg JB, Hibbs JB Jr. Endocytosis of red blood cells or haemoglobin by activated macrophages inhibits their tumoricidal effect. Nature 1977;269:245-247.
65. Esparza I, Green R, Schreiber RD. Inhibition of macrophage tumoricidal activity by immune complexes and altered erythrocytes. J Immunol 1983;131:2117-2121.
66. Feldman GM, Chuang EJ, Finbloom DS. IgG immune complexes inhibit IFN-gamma-induced transcription of the Fc gamma RI gene in human monocytes by preventing the tyrosine phosphorylation of the p91 (Stat1) transcription factor. J Immunol 1995;154:318-325.
67. Boekhoudt GH, Frazier-Jessen MR, Feldman GM. Immune complexes suppress IFN-gamma signaling by activation of the FcgammaRI pathway. J Leukoc Biol 2007;81:1086-1092.
68. Boekhoudt GH, McGrath AG, Swisher JF, Feldman GM. Immune complexes suppress IFN-gamma-induced responses in monocytes by activating discrete members of the SRC kinase family. J Immunol 2015;194:983-989.
69. Swisher JF, Haddad DA, McGrath AG, Boekhoudt GH, Feldman GM. IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcgammaRI. mAbs 2014;6:1377-1384.
70. Kimura T, Kihara H, Bhattacharyya S, Sakamoto H, Appella E, Siraganian RP. Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) peptides of the high affinity IgE receptor. J Biol Chem 1996;271:27962-27968.
71. Kimura T, Sakamoto H, Appella E, Siraganian RP. Conformational changes induced in the protein tyrosine kinase p72syk by tyrosine phosphorylation or by binding of phosphorylated immunoreceptor tyrosine-based activation motif peptides. Mol Cell Biol 1996;16:1471-1478.
72. Ben Mkaddem S, Aloulou M, Benhamou M, Monteiro RC. Role of FcgammaRIIIA (CD16) in IVIg-mediated anti-inflammatory function. J Clin Immunol 2014;34(Suppl.):S46-S50.
73. Ben Mkaddem S, et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest 2014;124:3945-3959.
74. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 2009;232:59-71.
75. Ivashkiv LB. How ITAMs inhibit signaling. Sci Signal 2011;4:pe20.
76. Gallo P, Goncalves R, Mosser DM. The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett 2010;133:70-77.
77. Dai XL, et al. Differential signal transduction, membrane trafficking, and immune effector functions mediated by Fc gamma RI versus Fc gamma RIIa. Blood 2009;114:318-327.
78. Ji JD, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med 2003;197:1573-1583.
79. Bezbradica JS, Rosenstein RK, Demarco RA, Brodsky I, Medzhitov R. A role for the ITAM signaling module in specifying cytokine-receptor functions. Nat Immunol 2014;15:333-342.
80. Ioan-Facsinay A, et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 2002;16:391-402.
81. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fc gamma receptor type I. J Exp Med 1998;188:217-222.
82. Lecocq M, Detry B, Guisset A, Pilette C. FcalphaRI-mediated inhibition of IL-12 production and priming by IFN-gamma of human monocytes and dendritic cells. J Immunol 2013;190:2362-2371.
83. Vogelpoel LT, et al. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat Commun 2014;5:5444.
84. Annunziata P, Pluchino S, Martino T, Guazzi G. High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis. J Neuroimmunol 1997;77:128-133.
85. Annunziata P, Cioni C, Cantalupo L, Di Genova G, Savellini GG, Cusi G. Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis. J Neuroimmunol 2013;256:62-70.
86. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
87. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs 2009;1:539-547.
88. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010;10:712-722.
89. Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006;80:10128-10138.
90. Yamada DH, et al. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 2015;42:379-390.
91. Wieland A, et al. Antibody effector functions mediated by Fcgamma-receptors are compromised during persistent viral infection. Immunity 2015;42:367-378.
92. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005;201:747-754.
93. Van Weyenbergh J, et al. Challenging the Th1 paradigm: a detrimental role for IFN-gamma and IFN-regulated CD64 in human leishmaniasis. Cytokine 2013;63:306.
94. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005;52:642-650.
95. Szalai AJ, et al. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003;48:1602-1611.
96. Rodriguez W, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006;54:325-335.
97. Zhang L, et al. C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. J Immunol 2015;194:5243-5252.
98. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002;169:7019-7025.
99. Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J Immunol 2009;182:1397-1403.
100. Crawford JR, Pilling D, Gomer RH. FcgammaRI mediates serum amyloid P inhibition of fibrocyte differentiation. J Leukoc Biol 2012;92:699-711.
101. Pilling D, Crawford JR, Verbeek JS, Gomer RH. Inhibition of murine fibrocyte differentiation by cross-linked IgG is dependent on FcgammaRI. J Leukoc Biol 2014;96:275-282.
102. Pilling D, Cox N, Vakil V, Verbeek JS, Gomer RH. The long pentraxin PTX3 promotes fibrocyte differentiation. PLoS ONE 2015;10:e0119709.
103. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. mAbs 2015;7:303-310.
104. Hristodorov D, Mladenov R, Huhn M, Barth S, Thepen T. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) 2012;4:676-694.
105. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
106. Magnusson SE, Wennerberg E, Matt P, Lindqvist U, Kleinau S. Dysregulated Fc receptor function in active rheumatoid arthritis. Immunol Lett 2014;162:200-206.
107. Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011;140:221-230.
108. Vos AC, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012;18:401-408.
109. Zhang H, et al. Mast cell deficiency exacerbates inflammatory bowel symptoms in interleukin-10-deficient mice. World J Gastroenterol 2014;20:9106-9115.
110. Braat H, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-759.
111. Atreya R, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014;20:313-318.
112. Hristodorov D, Mladenov R, Brehm H, Fischer R, Barth S, Thepen T. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy. mAbs 2014;6:1283-1289.
113. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013;6:1.
114. Valerius T, et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993;82:931-939.
115. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95:652-656.
116. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006;66:1261-1264.
117. van der Bij GJ, et al. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol 2010;53:677-685.
118. Otten MA, et al. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 2008;181:6829-6836.
119. Boross P, et al. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. Immunol Lett 2014;160:151-157.
120. Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol 2010;664:15-19.
121. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555.
122. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-322.
123. Pander J, et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011;17:5668-5673.
124. Jinushi M, Komohara Y. Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 2015;1855:123-130.
125. Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunother UK 2013;5:1075-1087.
126. Grugan KD, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012;189:5457-5466.
127. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-5789.
128. Canioni D, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-446.
129. Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J Immunother Cancer 2014;2:29-38.
130. Jiang XR, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011;10:101-111.
131. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098-1104.
132. Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 1996;106:427-433.
133. Suntharalingam G, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-1028.
134. + immune cells contribute to the TGN1412-triggered cytokine response. J Immunol 2014;192:2091-2098.
135. Ball C, et al. Antibody C region influences TGN1412-like functional activity in vitro. J Immunol 2012;189:5831-5840.
136. Lux A, et al. A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep 2014;7:236-248.
137. Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014;41:14-20.